Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ChatMDV: Reducing Technical Barriers in Bioinformatics Analysis using Large Language Models.

GigaScience·2026
Same author

A New Type of Nonsuppressible Viremia Produced by HIV-Infected Macrophage.

The Journal of infectious diseases·2026
Same author

Definition of Severity and Relapse for Vitiligo: An International Consensus Statement.

JAMA dermatology·2026
Same author

Service needs of people living with HIV in the UK (Positive Voices 2022): a cross-sectional survey.

The lancet. HIV·2026
Same author

Defining Important Aspects of Repigmentation in Vitiligo: Insights From Patients' Perspectives.

Pigment cell & melanoma research·2026
Same author

Iterative refinement of arbitrary micro-optical surfaces.

Optics express·2025

Related Experiment Video

Updated: Jun 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Using HIV resistance tests in clinical practice.

Stephen Taylor1, Ashini Jayasuriya, Erasmus Smit

  • 1Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK. steve.taylor@heartofengland.nhs.uk

The Journal of Antimicrobial Chemotherapy
|June 19, 2009
PubMed
Summary
This summary is machine-generated.

Genotypic resistance testing is crucial for managing HIV. This article guides clinicians on the optimal use of these tests in real-life scenarios, considering budget and time constraints for HIV-positive adults.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Related Experiment Videos

Last Updated: Jun 22, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Area of Science:

  • Virology
  • Clinical Medicine
  • Pharmacogenomics

Background:

  • Genotypic resistance testing (GRT) is integral to modern human immunodeficiency virus (HIV) management.
  • Established guidelines exist for GRT, yet optimal application remains a challenge for healthcare providers.
  • Resource limitations, including budget and time, complicate the strategic deployment of GRT.

Purpose of the Study:

  • To provide practical insights into the optimal application of genotypic resistance testing.
  • To address real-world clinical scenarios faced by healthcare professionals managing HIV-positive adults.
  • To enhance the effective utilization of resistance testing within resource-constrained environments.

Main Methods:

  • Discussion of clinical case studies illustrating diverse patient management situations.
  • Analysis of factors influencing the decision-making process for resistance testing.
  • Review of current literature and guidelines in the context of practical application.

Main Results:

  • Identification of specific clinical junctures where GRT provides significant value.
  • Demonstration of how GRT can inform treatment decisions in complex cases.
  • Highlighting strategies for maximizing the utility of GRT under practical constraints.

Conclusions:

  • Optimal application of genotypic resistance testing can significantly improve HIV management outcomes.
  • Strategic use of GRT, guided by clinical context, is essential for effective patient care.
  • Further exploration of resource-efficient GRT strategies is warranted for widespread implementation.